Taysha Gene Therapies, Inc. (TSHA)
5.075
+0.02
(+0.30%)
USD |
NASDAQ |
Sep 16, 16:00
5.075
0.00 (0.00%)
After-Hours: 16:03
Taysha Gene Therapies PE Ratio
PE Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical PE Ratio Data
| Date | Value |
|---|---|
| September 16, 2026 |
PE Ratio Definition
The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS Diluted (TTM). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.
PE Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PE Ratio Benchmarks
| Altimmune, Inc. | -- |
| Protalix Biotherapeutics, Inc. | 11.82 |
| Humacyte, Inc. | -- |
| Agenus, Inc. | 2.720 |
| Amgen, Inc. | 23.38 |
PE Ratio Related Metrics
| PS Ratio | 317.83 |
| PEG Ratio | -0.5566 |
| Price to Book Value | 4.263 |
| Price | 5.075 |
| Earnings Yield | -8.52% |
| Market Cap | 1.651B |
| PEGY Ratio | -0.5566 |